Quantcast

Latest gabapentin Stories

2008-09-23 18:00:13

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ProAir(R) HFA (albuterol sulfate) Inhalation Aerosol for use in patients as young as 4 years of age. Previously, ProAir HFA had been indicated for use in patients aged 12 and older. In clinical studies, ProAir HFA, the market leading albuterol sulfate inhaler,(1) exhibited significant bronchodilator efficacy in pediatric asthmatics aged 4 to 11 years. ProAir HFA provides...

2008-09-22 15:00:53

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the introduction of Nicardipine Hydrochloride Injection, 2.5 mg/mL, which is AP-rated to EKR Therapeutics' hypertension treatment Cardene(R) I.V. Teva's product is the first alternative to the brand product, which had annual sales of approximately $181 million in the United States for the twelve months ended June 30, 2008, according to IMS sales data. Teva is manufacturing and distributing the product, under license, as...

2008-09-18 15:00:38

Depomed, Inc. (NASDAQ: DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, September 23, 2008 at 8:30 a.m. ET during the UBS Global Life Sciences Conference to be held in New York City. Interested parties can access a live, or archived, webcast of the presentation on the company's website at www.depomedinc.com. About Depomed Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and...

2008-09-18 15:00:38

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced new data from the longest prospective study of treatment to relapsing-remitting multiple sclerosis (RRMS), which proves robust efficacy and safety of COPAXONE(R) (glatiramer acetate injection). Findings demonstrated that more than 80 percent of patients were able to walk unassisted following 15 years of treatment and average disease duration of 22 years. The majority of the 100 patients in the study experienced either stable...

2008-09-18 12:00:40

Depomed, a specialty pharmaceutical company, has announced the enrollment and dosing of the first patient in Breeze 1, the first of two pivotal Phase III clinical trials in Depomed's registration program for Gabapentin GR for the treatment of menopausal hot flashes. Depomed's Phase III registration program for Gabapentin GR in menopausal hot flashes includes two randomized, double-blind, placebo-controlled studies of approximately 540 patients per study. In each study, patients will be...

2008-09-17 06:00:36

Depomed, Inc. (NASDAQ:DEPO) announced today the enrollment and dosing of the first patient in Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed's registration program for Gabapentin GR(R) for the treatment of menopausal hot flashes. "We believe that Gabapentin GR could become the first single-agent, safe, effective, non-hormonal and non-antidepressant treatment to address menopausal hot flashes, one of the largest unmet needs in women's health. The significant decline in...

2008-09-16 09:00:53

RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline and XenoPort, Inc. announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). RLS affects an estimated 12 million people in the United States and can result in...

2008-09-15 09:00:11

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced presentations of several new studies at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal. New data will be presented on COPAXONE(R) (glatiramer acetate injection), a leading therapy for relapsing-remitting multiple sclerosis (RRMS) treatment, covering early treatment with COPAXONE(R), long-term efficacy and safety. In addition to Teva's post-marketing studies of COPAXONE(R) in RRMS, the...

2008-09-05 03:00:06

WASHINGTON - Cody Miller was a high school football player who was allergic to ragweed. Douglas Briggs was a doctor coping with pain from a back injury. Both are now dead, driven to suicide, their families believe, when drugs prescribed to relieve physical symptoms upset their mental and emotional balance. Federal drug regulators are investigating to see whether the families could be right. Until now, the Food and Drug Administration's attention to the suicide risks of...

2008-09-03 09:00:07

Plexxikon Inc. today announced that it has initiated a Phase 1 human clinical trial for PLX5568, a novel kinase inhibitor targeted for the treatment of at least two major indications with unmet medical needs: pain as well as polycystic kidney disease (PKD). PLX5568 has demonstrated robust preclinical efficacy in multiple pain models, including neuropathic pain as well as acute and inflammatory pain. In addition, PLX5568 has demonstrated compelling efficacy in multiple preclinical models of...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related